Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06215040
Recruiting Observational

The Treatment Effect for Asymptomatic Common Bile Duct Stone

NCT06215040 · tracked via the Priya Life Science South Korea tracker
Sponsor
Kyungpook National University Hospital
Phase
Observational
Started
2024-01-02
Last updated
2024-01-22

Condition(s) studied

CholedocholithiasisAsymptomatic ConditionQuality of Life

Investigational drug(s) / intervention(s)

Endoscopic retrograde cholangiopancratography

Endoscopic retrograde cholangiopancratography: common bile duct stone removal

Study summary

This study is prospective, multicenter study for identify the characteristics of asymptomatic common bile duct stones and effectiveness of treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * diagnosed as common bile duct stone by image modality examination * agreement for this study enrollment Exclusion Criteria: * no definite common bile duct stone by image modality examination * symptomatic patients who complain with fever/abdominal pain that compatible with common bile duct stone related symptom * previously diagnosed as pancreatobiliary malignancy * previously treated by endoscopic or percutaneous treatment for bile duct stones * severe cardio or pulmonary disease * pregnancy or possibility of pregnancy * who do not agree with study enrollment

Primary outcome measure(s)

  • Score of quality of life — 3 months
    Compare the quality of life before and after treatment

Trial sites (1)

FacilityCityRegionStatus
Kyungpook National University Hospital Daegu Gyungsangbok-do Recruiting

More Kyungpook National University Hospital trials in South Korea

Early Commencement of Adjuvant Chemotherapy for Colon Cancer Active, not recruiting
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer Active, not recruiting
Analysis of Biomarkers From Patients With Chorioretinal Diseases Recruiting
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer Active, not recruiting
Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk Recruiting

Other trials for the same condition

Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients Recruiting
SupporTive Care At Home Research for Patients With Advanced Cancer (STAHR-cancer) Recruiting
QOL and Mental Health Using APD With Remote Monitoring System Enrolling by invitation
Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer Recruiting
International CIPN Assessment and Validation Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06215040 on ClinicalTrials.gov ↗ ← All trials in South Korea